Angiotensin type 2 receptors: Role in aging and neuroinflammation in the substantia nigra

Highlights

• The AT1/NADPH-oxidase axis enhances aging, neuroinflammation and neurodegeneration.

• Nigral AT2 decreases with aging and AT2 deletion induces aging-related changes.

• AT2 inhibits AT1 levels and pro-inflammatory markers in nigra, microglia and neurons.

• The pathway AT2/NO/ODQ/Sp1 mediates the regulation of the AT1 expression by AT2.

• Mas receptors are also involved in the regulation of AT1 expression by AT2.

Abstract

Overactivity of the angiotensin-type-1 receptor (AT1)/NADPH-oxidase axis enhances aging processes, neuroinflammation and neurodegeneration. The role of AT2 receptors in the above-mentioned AT1-related effects in the aged brain, particularly substantia nigra, was investigated in this study. In the nigra, we observed a progressive decrease in AT2 mRNA expression with aging, and AT2 deletion led to changes in spontaneous motor behavior, dopamine receptors, renin-angiotensin system, and pro-oxidative and pro-inflammatory markers similar to those observed in aged wild type (WT) mice. Both aged WT mice and young AT2 KO mice showed an increased AT1, decreased MAS receptor and increased angiotensinogen mRNA and/or protein expression, as well as upregulation of pro-oxidative and pro-inflammatory markers. In cultures of microglial cells, activation of AT2 receptors inhibited the LPS-induced increase in AT1 mRNA and protein expression and neuroinflammatory markers. Both in AT2 KO microglial cultures and microglia obtained from adult AT2 KO mice, an increase in AT1 mRNA expression was observed. In cultured dopaminergic neurons, AT2 activation down-regulated AT1 mRNA and protein, and dopaminergic neurons from adult AT2 KO mice showed upregulation of AT1 mRNA expression. Both in microglia and dopaminergic neurons the pathway AT2/nitric oxide/cyclic guanosine monophosphate mediates the regulation of the AT1 mRNA and protein expression through downregulation of the Sp1 transcription factor. MAS receptors are also involved in the regulation of AT1 mRNA and protein expression by AT2. The results suggest that an aging-related decrease in AT2 expression plays a major role in the aging-related AT1 overexpression and AT1-related pro-inflammatory pro-oxidative effects.

Introduction

Several previous studies have shown that the tissue renin angiotensin system (RAS) plays a role in the aging process. This has been related to over activity of angiotensin II (AngII) type 1 receptors (AT1) and the downstream pro-oxidative pro-inflammatory axis AT1/NADPH-oxidase/superoxide. Consistent with this, AT1 deletion in rodents (Benigni et al., 2009, Cassis et al., 2010) and AT1 variations in humans associated to reduced AT1 protein (Benigni et al., 2013) are associated with prolonged life span. Overactivity of the AT1/NADPH-oxidase axis has been involved in the aging-related pro-inflammatory changes observed in several tissues (i.e. inflamm-aging; Franceschi et al., 2000, Marchesi et al., 2008, Labandeira-Garcia et al., 2017). Furthermore, mutual interaction between RAS and dopaminergic (DA) system to regulate major functional effects has been demonstrated in peripheral organs, such as the kidney (Carey, 2013, Gildea, 2009), and in the brain, particularly in a major dopaminergic center such as the substantia nigra (SN) (Villar-Cheda 2010, 2014). The second major AngII receptor (AngII type 2, AT2) is considered to counteract AT1 effects and functionally acts as an AT1 antagonist (AbdAlla et al., 2001, Steckelings et al., 2005). A number of mechanisms involved in the counteracting effects of AT2 on AT1 signaling have been suggested in different types of cells (Padia and Carey, 2013, Patel and Hussain, 2018, Steckelings et al., 2005), although it is a complex issue that has not been totally clarified. It has been classically considered that AT2 receptors are very abundant and play a major role in embryonic tissues, and decrease in adult tissues (Millan et al., 1991, Schütz et al., 1996). However, this may be the result of data from early autoradiographic and ligand binding studies, which primarily detected receptors on the cell surface. More recent studies using western blot, RT-PCR and cell fractionation methods have revealed abundant AT2 receptors in adult tissues, including brain (Valenzuela et al., 2016, Villar-Cheda et al., 2017). However, the role of AT2 and the AT1/AT2 interaction in aging and inflammation, particularly brain aging and neuroinflammation remains unclear.

Aging and neuroinflammation are major factors involved in development and progression of Parkinson’s disease, which is characterized by neuronal death and dysregulation of the dopaminergic function. Previous studies have discovered a local RAS in the SN of rodents and primates, including humans (Garrido-Gil et al., 2013, Valenzuela et al., 2010). The nigral RAS, and particularly the overactivity of the AT1/NADPH-oxidase/superoxide axis, has been shown to play a major role in aging-related changes (Villar-Cheda et al., 2012, Villar-Cheda et al., 2014), neuroinflammation (Labandeira-Garcia et al., 2017, Rodriguez-Perez et al., 2018) and dopaminergic neurodegeneration (Grammatopoulos et al., 2007, Labandeira-Garcia et al., 2013). In addition, several studies have shown that activation of the nigral AT1 increases dopamine levels (Brown et al., 1996, Medelsohn et al., 1993), suggesting that a major physiologic role of the nigral RAS is regulation of the dopaminergic function. However, overactivity of the AT1/NADPH-oxidase axis (e.g. as a compensatory upregulation to increase low dopamine levels) may accelerate aging processes, neuroinflammation and neurodegeneration (Labandeira-García et al., 2014, Labandeira-Garcia et al., 2016). The role of AT2 in the above mentioned AT1-related changes in the brain, and particularly in the nigrostriatal system, is still unclear. In the present study we have used young and aged mice, AT2 knockout (KO) and wild type (WT) mice, as well as microglial and neuronal cultures and microglia and dopaminergic neurons isolated from adult brains to investigate the role of AT2 receptors in the regulation of the AT1 pro-oxidative-proinflammatory axis, and particularly the role of AT2 in aging-related AT1 overexpression and pro-inflammatory changes.